A post hoc MRI look at 55 people, shown at EASD 2026, found average liver fat dropped from 8.8% to 3.1% by week 72. No placebo comparison was reported.
Recap by typeshit. Full story at Pharmacy Times.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The CWRU professor studied 1 million Americans with type 2 diabetes, and stresses the result is an association, not proof semaglutide prevents Alzheimer's.
More than half had never used a GLP-1 drug before, suggesting the pill is bringing in new patients rather than just switchers, researchers say.
Loading…